I dont think they will ever be able to move on
Oh they certainly will when MSB reaches 'sustainable commercialisation'.
An authoritative-sounding term, which neatly fails to mention the risk vs reward analysis necessary in evaluation any biotech.
In fact it's a complete disregard of the colossal reward in the overall equation, and one which you miss out on if you wait for the much vaunted 'sustainable commercialisation' to materialise along with it the rush to higher share price. It's a wonder whytee never mentions it really, anything to distract...a mere trifle will do!
Ann: Mesoblast Type A Meeting with FDA, page-211
-
- There are more pages in this discussion • 364 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |